Randomized Trialhigh evidence
Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.
The lancet. Diabetes & endocrinology·June 1, 2026·PMID 42009015
Why it mattersThis trial provides the first efficacy and safety data for the cagrilintide-semaglutide combination specifically in an East Asian population, where obesity definitions and metabolic responses may differ. The substantial additional weight loss over semaglutide alone supports its potential role in managing obesity in this demographic.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled